Table 3.
Associations with nephrosclerosis abnormal versus normal for age in donors, patients with tumor, and patients with kidney disease (age-adjusted)
| Nephrosclerosis Measure | %GSG | %IFTA | IFTA Foci Density | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Cohort | Kidney Donors | Patients with Kidney Tumor | Patients with Kidney Disease | Kidney Donors | Patients with Kidney Tumor | Patients with Kidney Disease | Kidney Donors | Patients with Kidney Tumor | Patients with Kidney Disease |
| Clinical characteristics | |||||||||
| Men | 0.66 (0.47 to 0.93) | 0.69 (0.52 to 0.90) | 1.21 (0.77 to 1.91) | 1.79 (1.31 to 2.45) | 1.36 (1.04 to 1.78) | 1.83 (1.13 to 2.98) | 1.51 (1.11 to 2.06) | 1.00 (0.73 to 1.37) | 1.76 (1.10 to 2.82) |
| Black | 2.47 (1.25 to 4.89) | 2.53 (1.03 to 6.23) | 1.80 (0.54 to 6.04) | 1.72 (0.82 to 3.64) | 0.31 (0.07 to 1.33) | 1.18 (0.31 to 4.56) | 1.25 (0.54 to 2.92) | 0.94 (0.27 to 3.20) | 1.36 (0.35 to 5.22) |
| BMI, per SD | 0.99 (0.85 to 1.17) | 1.17 (1.02 to 1.34) | 0.99 (0.80 to 1.23) | 1.04 (0.89 to 1.21) | 1.29 (1.14 to 1.46) | 1.00 (0.80 to 1.25) | 0.92 (0.78 to 1.08) | 1.05 (0.91 to 1.22) | 1.13 (0.91 to 1.41) |
| Diabetes | — | 1.83 (1.29 to 2.61) | 2.25 (1.31 to 3.89) | — | 2.21 (1.59 to 3.08) | 4.32 (2.03 to 9.22) | — | 1.20 (0.78 to 1.83) | 3.46 (1.75 to 6.86) |
| Hypertension | 1.70 (1.14 to 2.55) | 2.47 (1.73 to 3.53) | 2.35 (1.37 to 4.02) | 1.78 (1.20 to 2.64) | 2.15 (1.58 to 2.92) | 2.18 (1.27 to 3.75) | 1.91 (1.30 to 2.80) | 2.04 (1.40 to 2.97) | 3.37 (1.95 to 5.81) |
| GFR, per SDa | 1.10 (0.93 to 1.30) | 0.50 (0.43 to 0.59) | 0.57 (0.43 to 0.76) | 0.96 (0.81 to 1.15) | 0.56 (0.48 to 0.65) | 0.62 (0.46 to 0.83) | 0.88 (0.74 to 1.05) | 0.74 (0.63 to 0.87) | 0.85 (0.64 to 1.12) |
| 24-h protein, per doubling | 1.09 (0.88 to 1.34) | 1.22 (1.12 to 1.33) | 1.16 (1.04 to 1.29) | 1.35 (1.10 to 1.65) | 1.26 (1.16 to 1.36) | 1.18 (1.06 to 1.32) | 1.24 (1.01 to 1.51) | 1.08 (0.98 to 1.19) | 1.18 (1.06 to 1.32) |
| Nephron size | |||||||||
| NSG volume, mm3 | 0.92 (0.78 to 1.09) | 1.38 (1.21 to 1.56) | 1.03 (0.82 to 1.29) | 1.13 (0.98 to 1.31) | 1.41 (1.25 to 1.59) | 1.11 (0.86 to 1.43) | 1.04 (0.90 to 1.21) | 0.96 (0.82 to 1.12) | 1.16 (0.90 to 1.50) |
| Non-IFTA cortex per glomerulus, mm3 | 1.15 (1.00 to 1.32) | 1.62 (1.41 to 1.85) | 1.45 (1.10 to 1.91) | 1.02 (0.88 to 1.19) | 1.31 (1.16 to 1.48) | 1.40 (0.98 to 2.10) | 0.87 (0.73 to 1.04) | 0.90 (0.76 to 1.06) | 1.51 (1.04 to 2.19) |
| Arteriosclerosis | |||||||||
| % luminal stenosis | 1.06 (0.90 to 1.24) | 1.74 (1.47 to 2.07) | 1.43 (1.11 to 1.84) | 1.07 (0.92 to 1.24) | 1.59 (1.37 to 1.86) | 1.35 (1.03 to 1.76) | 0.98 (0.84 to 1.14) | 1.32 (1.11 to 1.58) | 1.64 (1.25 to 2.16) |
Data shown as odds ratios (95% confidence interval), per SD for continuous measures. GSG, globally sclerotic glomeruli; BMI, body mass index; NSG, nonsclerosed glomeruli; IFTA, interstitial fibrosis and tubular atrophy.
a
Measured GFR for donors and eGFR for patients with tumor and patients with kidney disease.